Barriers to Infection of Human Cells by Feline Leukemia Virus: Insights into Resistance to Zoonosis

The human genome displays a rich fossil record of past gammaretrovirus infections, yet no current epidemic is evident, despite environmental exposure to viruses that infect human cells in vitro . Feline leukemia viruses (FeLVs) rank high on this list, but neither domestic nor workplace exposure has...

Full description

Saved in:
Bibliographic Details
Published inJournal of virology Vol. 91; no. 5
Main Authors Terry, Anne, Kilbey, Anna, Naseer, Asif, Levy, Laura S., Ahmad, Shamim, Watts, Ciorsdaidh, Mackay, Nancy, Cameron, Ewan, Wilson, Sam, Neil, James C.
Format Journal Article
LanguageEnglish
Published United States American Society for Microbiology 01.03.2017
Subjects
Online AccessGet full text
ISSN0022-538X
1098-5514
1070-6321
1098-5514
DOI10.1128/JVI.02119-16

Cover

Abstract The human genome displays a rich fossil record of past gammaretrovirus infections, yet no current epidemic is evident, despite environmental exposure to viruses that infect human cells in vitro . Feline leukemia viruses (FeLVs) rank high on this list, but neither domestic nor workplace exposure has been associated with detectable serological responses. Nonspecific inactivation of gammaretroviruses by serum factors appears insufficient to explain these observations. To investigate further, we explored the susceptibilities of primary and established human cell lines to FeLV-B, the most likely zoonotic variant. Fully permissive infection was common in cancer-derived cell lines but was also a feature of nontransformed keratinocytes and lung fibroblasts. Cells of hematopoietic origin were generally less permissive and formed discrete groups on the basis of high or low intracellular protein expression and virion release. Potent repression was observed in primary human blood mononuclear cells and a subset of leukemia cell lines. However, the early steps of reverse transcription and integration appear to be unimpaired in nonpermissive cells. FeLV-B was subject to G→A hypermutation with a predominant APOBEC3G signature in partially permissive cells but was not mutated in permissive cells or in nonpermissive cells that block secondary viral spread. Distinct cellular barriers that protect primary human blood cells are likely to be important in protection against zoonotic infection with FeLV. IMPORTANCE Domestic exposure to gammaretroviruses such as feline leukemia viruses (FeLVs) occurs worldwide, but the basis of human resistance to infection remains incompletely understood. The potential threat is evident from the human genome sequence, which reveals many past epidemics of gammaretrovirus infection, and from recent cross-species jumps of gammaretroviruses from rodents to primates and marsupials. This study examined resistance to infection at the cellular level with the most prevalent human cell-tropic FeLV variant, FeLV-B. We found that blood cells are uniquely resistant to infection with FeLV-B due to the activity of cellular enzymes that mutate the viral genome. A second block, which appears to suppress viral gene expression after the viral genome has integrated into the host cell genome, was identified. Since cells derived from other normal human cell types are fully supportive of FeLV replication, innate resistance of blood cells could be critical in protecting against cross-species infection.
AbstractList The human genome displays a rich fossil record of past gammaretrovirus infections, yet no current epidemic is evident, despite environmental exposure to viruses that infect human cells in vitro. Feline leukemia viruses (FeLVs) rank high on this list, but neither domestic nor workplace exposure has been associated with detectable serological responses. Nonspecific inactivation of gammaretroviruses by serum factors appears insufficient to explain these observations. To investigate further, we explored the susceptibilities of primary and established human cell lines to FeLV-B, the most likely zoonotic variant. Fully permissive infection was common in cancer-derived cell lines but was also a feature of nontransformed keratinocytes and lung fibroblasts. Cells of hematopoietic origin were generally less permissive and formed discrete groups on the basis of high or low intracellular protein expression and virion release. Potent repression was observed in primary human blood mononuclear cells and a subset of leukemia cell lines. However, the early steps of reverse transcription and integration appear to be unimpaired in nonpermissive cells. FeLV-B was subject to G→A hypermutation with a predominant APOBEC3G signature in partially permissive cells but was not mutated in permissive cells or in nonpermissive cells that block secondary viral spread. Distinct cellular barriers that protect primary human blood cells are likely to be important in protection against zoonotic infection with FeLV. IMPORTANCE Domestic exposure to gammaretroviruses such as feline leukemia viruses (FeLVs) occurs worldwide, but the basis of human resistance to infection remains incompletely understood. The potential threat is evident from the human genome sequence, which reveals many past epidemics of gammaretrovirus infection, and from recent cross-species jumps of gammaretroviruses from rodents to primates and marsupials. This study examined resistance to infection at the cellular level with the most prevalent human cell-tropic FeLV variant, FeLV-B. We found that blood cells are uniquely resistant to infection with FeLV-B due to the activity of cellular enzymes that mutate the viral genome. A second block, which appears to suppress viral gene expression after the viral genome has integrated into the host cell genome, was identified. Since cells derived from other normal human cell types are fully supportive of FeLV replication, innate resistance of blood cells could be critical in protecting against cross-species infection.
The human genome displays a rich fossil record of past gammaretrovirus infections, yet no current epidemic is evident, despite environmental exposure to viruses that infect human cells in vitro Feline leukemia viruses (FeLVs) rank high on this list, but neither domestic nor workplace exposure has been associated with detectable serological responses. Nonspecific inactivation of gammaretroviruses by serum factors appears insufficient to explain these observations. To investigate further, we explored the susceptibilities of primary and established human cell lines to FeLV-B, the most likely zoonotic variant. Fully permissive infection was common in cancer-derived cell lines but was also a feature of nontransformed keratinocytes and lung fibroblasts. Cells of hematopoietic origin were generally less permissive and formed discrete groups on the basis of high or low intracellular protein expression and virion release. Potent repression was observed in primary human blood mononuclear cells and a subset of leukemia cell lines. However, the early steps of reverse transcription and integration appear to be unimpaired in nonpermissive cells. FeLV-B was subject to G→A hypermutation with a predominant APOBEC3G signature in partially permissive cells but was not mutated in permissive cells or in nonpermissive cells that block secondary viral spread. Distinct cellular barriers that protect primary human blood cells are likely to be important in protection against zoonotic infection with FeLV.IMPORTANCE Domestic exposure to gammaretroviruses such as feline leukemia viruses (FeLVs) occurs worldwide, but the basis of human resistance to infection remains incompletely understood. The potential threat is evident from the human genome sequence, which reveals many past epidemics of gammaretrovirus infection, and from recent cross-species jumps of gammaretroviruses from rodents to primates and marsupials. This study examined resistance to infection at the cellular level with the most prevalent human cell-tropic FeLV variant, FeLV-B. We found that blood cells are uniquely resistant to infection with FeLV-B due to the activity of cellular enzymes that mutate the viral genome. A second block, which appears to suppress viral gene expression after the viral genome has integrated into the host cell genome, was identified. Since cells derived from other normal human cell types are fully supportive of FeLV replication, innate resistance of blood cells could be critical in protecting against cross-species infection.The human genome displays a rich fossil record of past gammaretrovirus infections, yet no current epidemic is evident, despite environmental exposure to viruses that infect human cells in vitro Feline leukemia viruses (FeLVs) rank high on this list, but neither domestic nor workplace exposure has been associated with detectable serological responses. Nonspecific inactivation of gammaretroviruses by serum factors appears insufficient to explain these observations. To investigate further, we explored the susceptibilities of primary and established human cell lines to FeLV-B, the most likely zoonotic variant. Fully permissive infection was common in cancer-derived cell lines but was also a feature of nontransformed keratinocytes and lung fibroblasts. Cells of hematopoietic origin were generally less permissive and formed discrete groups on the basis of high or low intracellular protein expression and virion release. Potent repression was observed in primary human blood mononuclear cells and a subset of leukemia cell lines. However, the early steps of reverse transcription and integration appear to be unimpaired in nonpermissive cells. FeLV-B was subject to G→A hypermutation with a predominant APOBEC3G signature in partially permissive cells but was not mutated in permissive cells or in nonpermissive cells that block secondary viral spread. Distinct cellular barriers that protect primary human blood cells are likely to be important in protection against zoonotic infection with FeLV.IMPORTANCE Domestic exposure to gammaretroviruses such as feline leukemia viruses (FeLVs) occurs worldwide, but the basis of human resistance to infection remains incompletely understood. The potential threat is evident from the human genome sequence, which reveals many past epidemics of gammaretrovirus infection, and from recent cross-species jumps of gammaretroviruses from rodents to primates and marsupials. This study examined resistance to infection at the cellular level with the most prevalent human cell-tropic FeLV variant, FeLV-B. We found that blood cells are uniquely resistant to infection with FeLV-B due to the activity of cellular enzymes that mutate the viral genome. A second block, which appears to suppress viral gene expression after the viral genome has integrated into the host cell genome, was identified. Since cells derived from other normal human cell types are fully supportive of FeLV replication, innate resistance of blood cells could be critical in protecting against cross-species infection.
The human genome displays a rich fossil record of past gammaretrovirus infections, yet no current epidemic is evident, despite environmental exposure to viruses that infect human cells Feline leukemia viruses (FeLVs) rank high on this list, but neither domestic nor workplace exposure has been associated with detectable serological responses. Nonspecific inactivation of gammaretroviruses by serum factors appears insufficient to explain these observations. To investigate further, we explored the susceptibilities of primary and established human cell lines to FeLV-B, the most likely zoonotic variant. Fully permissive infection was common in cancer-derived cell lines but was also a feature of nontransformed keratinocytes and lung fibroblasts. Cells of hematopoietic origin were generally less permissive and formed discrete groups on the basis of high or low intracellular protein expression and virion release. Potent repression was observed in primary human blood mononuclear cells and a subset of leukemia cell lines. However, the early steps of reverse transcription and integration appear to be unimpaired in nonpermissive cells. FeLV-B was subject to G→A hypermutation with a predominant APOBEC3G signature in partially permissive cells but was not mutated in permissive cells or in nonpermissive cells that block secondary viral spread. Distinct cellular barriers that protect primary human blood cells are likely to be important in protection against zoonotic infection with FeLV. Domestic exposure to gammaretroviruses such as feline leukemia viruses (FeLVs) occurs worldwide, but the basis of human resistance to infection remains incompletely understood. The potential threat is evident from the human genome sequence, which reveals many past epidemics of gammaretrovirus infection, and from recent cross-species jumps of gammaretroviruses from rodents to primates and marsupials. This study examined resistance to infection at the cellular level with the most prevalent human cell-tropic FeLV variant, FeLV-B. We found that blood cells are uniquely resistant to infection with FeLV-B due to the activity of cellular enzymes that mutate the viral genome. A second block, which appears to suppress viral gene expression after the viral genome has integrated into the host cell genome, was identified. Since cells derived from other normal human cell types are fully supportive of FeLV replication, innate resistance of blood cells could be critical in protecting against cross-species infection.
The human genome displays a rich fossil record of past gammaretrovirus infections, yet no current epidemic is evident, despite environmental exposure to viruses that infect human cells in vitro . Feline leukemia viruses (FeLVs) rank high on this list, but neither domestic nor workplace exposure has been associated with detectable serological responses. Nonspecific inactivation of gammaretroviruses by serum factors appears insufficient to explain these observations. To investigate further, we explored the susceptibilities of primary and established human cell lines to FeLV-B, the most likely zoonotic variant. Fully permissive infection was common in cancer-derived cell lines but was also a feature of nontransformed keratinocytes and lung fibroblasts. Cells of hematopoietic origin were generally less permissive and formed discrete groups on the basis of high or low intracellular protein expression and virion release. Potent repression was observed in primary human blood mononuclear cells and a subset of leukemia cell lines. However, the early steps of reverse transcription and integration appear to be unimpaired in nonpermissive cells. FeLV-B was subject to G→A hypermutation with a predominant APOBEC3G signature in partially permissive cells but was not mutated in permissive cells or in nonpermissive cells that block secondary viral spread. Distinct cellular barriers that protect primary human blood cells are likely to be important in protection against zoonotic infection with FeLV. IMPORTANCE Domestic exposure to gammaretroviruses such as feline leukemia viruses (FeLVs) occurs worldwide, but the basis of human resistance to infection remains incompletely understood. The potential threat is evident from the human genome sequence, which reveals many past epidemics of gammaretrovirus infection, and from recent cross-species jumps of gammaretroviruses from rodents to primates and marsupials. This study examined resistance to infection at the cellular level with the most prevalent human cell-tropic FeLV variant, FeLV-B. We found that blood cells are uniquely resistant to infection with FeLV-B due to the activity of cellular enzymes that mutate the viral genome. A second block, which appears to suppress viral gene expression after the viral genome has integrated into the host cell genome, was identified. Since cells derived from other normal human cell types are fully supportive of FeLV replication, innate resistance of blood cells could be critical in protecting against cross-species infection.
Author Ahmad, Shamim
Wilson, Sam
Watts, Ciorsdaidh
Mackay, Nancy
Neil, James C.
Cameron, Ewan
Kilbey, Anna
Terry, Anne
Levy, Laura S.
Naseer, Asif
Author_xml – sequence: 1
  givenname: Anne
  surname: Terry
  fullname: Terry, Anne
  organization: MRC University of Glasgow Centre for Virus Research, University of Glasgow, Glasgow, United Kingdom
– sequence: 2
  givenname: Anna
  surname: Kilbey
  fullname: Kilbey, Anna
  organization: MRC University of Glasgow Centre for Virus Research, University of Glasgow, Glasgow, United Kingdom
– sequence: 3
  givenname: Asif
  surname: Naseer
  fullname: Naseer, Asif
  organization: MRC University of Glasgow Centre for Virus Research, University of Glasgow, Glasgow, United Kingdom
– sequence: 4
  givenname: Laura S.
  surname: Levy
  fullname: Levy, Laura S.
  organization: Tulane University, New Orleans, Louisiana, USA
– sequence: 5
  givenname: Shamim
  surname: Ahmad
  fullname: Ahmad, Shamim
  organization: Tulane University, New Orleans, Louisiana, USA
– sequence: 6
  givenname: Ciorsdaidh
  surname: Watts
  fullname: Watts, Ciorsdaidh
  organization: MRC University of Glasgow Centre for Virus Research, University of Glasgow, Glasgow, United Kingdom
– sequence: 7
  givenname: Nancy
  surname: Mackay
  fullname: Mackay, Nancy
  organization: MRC University of Glasgow Centre for Virus Research, University of Glasgow, Glasgow, United Kingdom
– sequence: 8
  givenname: Ewan
  surname: Cameron
  fullname: Cameron, Ewan
  organization: School of Veterinary Medicine, University of Glasgow, Glasgow, United Kingdom
– sequence: 9
  givenname: Sam
  surname: Wilson
  fullname: Wilson, Sam
  organization: MRC University of Glasgow Centre for Virus Research, University of Glasgow, Glasgow, United Kingdom
– sequence: 10
  givenname: James C.
  surname: Neil
  fullname: Neil, James C.
  organization: MRC University of Glasgow Centre for Virus Research, University of Glasgow, Glasgow, United Kingdom
BackLink https://www.ncbi.nlm.nih.gov/pubmed/28031367$$D View this record in MEDLINE/PubMed
BookMark eNpdUctu1DAUtVARnRZ2rJGXLJpy_UjisECiI0oHjVQJQYXYWI7npnVJ7MFOiubv8TClr5Wl6_PQOeeA7PngkZDXDI4Z4-rdl4vFMXDGmoJVz8iMQaOKsmRyj8wAOC9KoX7sk4OUrgGYlJV8Qfa5AsFEVc-IPTExOoyJjoEufId2dMHT0NGzaTCezrHvE2039BR755EucfqFgzP0wsUpvc-U5C6vxkSdzwJfMbk0Gm9xK_czBB_y4SV53pk-4avb95B8P_30bX5WLM8_L-Yfl4UVSo5FVytsjZG8k1ACIlS15SDQmLKpu6ZthEKFuDJS8bpUsIJKyFZUUqoaoFPikBQ73cmvzeaP6Xu9jm4wcaMZ6G1Z-vrG6X9laVZl_Icdfj21A64s-jGae04wTj_-8e5KX4YbXQpoGsmywNtbgRh-T5hGPbhkc2PGY5iSZqqUDCqmRIa-eeh1Z_J_iQzgO4CNIaWInbZuNNsxsrXr7xLkuR8mOHpCehr4EfwvdBqq3w
CitedBy_id crossref_primary_10_3390_v10040186
crossref_primary_10_1371_journal_pbio_3000217
crossref_primary_10_1128_MRA_00233_20
crossref_primary_10_1016_j_intimp_2017_08_028
crossref_primary_10_1128_JVI_00020_21
crossref_primary_10_3390_v12030335
Cites_doi 10.1128/JVI.00046-11
10.1038/ncb2879
10.1002/ijc.2910210103
10.1128/jvi.38.2.688-703.1981
10.1073/pnas.1304704110
10.1128/JVI.02411-10
10.1016/S0021-9258(18)47267-5
10.1093/nar/gkh554
10.1371/journal.ppat.1004145
10.1016/j.virol.2010.11.011
10.1128/jvi.71.11.8116-8123.1997
10.1084/jem.182.5.1345
10.1038/ni.3156
10.1099/0022-1317-71-2-343
10.1073/pnas.1217399110
10.1038/2241208a0
10.1038/296156a0
10.1128/jvi.58.3.825-834.1986
10.1016/0042-6822(80)90173-7
10.1016/j.jmb.2004.01.046
10.1371/journal.pone.0004744
10.1292/jvms.70.1383
10.1038/35057062
10.1099/0022-1317-73-11-2839
10.1128/jvi.68.4.2458-2467.1994
10.1128/JVI.02326-12
10.1128/jvi.68.4.2151-2160.1994
10.1007/s00705-011-0925-z
10.1038/nature00939
10.1073/pnas.74.5.1908
10.1126/science.1251343
10.2460/javma.2000.217.1475
10.1128/JVI.73.8.6500-6505.1999
10.1038/srep12230
10.1006/viro.1994.1597
10.1126/science.168.3935.1098
10.1371/journal.pgen.1004167
10.1126/science.287.5459.1828
10.1128/CVI.00705-14
10.1038/sj.onc.1209043
10.7589/2014-04-114
10.1016/0042-6822(71)90266-2
10.1128/jvi.62.3.722-731.1988
10.1038/nature16965
10.1128/jvi.68.12.8296-8303.1994
10.1186/1742-4690-9-112
10.1182/blood.V95.3.1093.003k01_1093_1099
10.1128/JVI.79.10.6478-6486.2005
10.1038/332731a0
10.1371/journal.pone.0154070
10.1128/JVI.02745-15
10.1128/JVI.00839-06
10.1002/ijc.2910210314
10.1128/JVI.80.7.3378-3385.2006
10.1128/jvi.68.12.8001-8007.1994
10.1128/MCB.01293-14
ContentType Journal Article
Copyright Copyright © 2017 Terry et al.
Copyright © 2017 Terry et al. 2017 Terry et al.
Copyright_xml – notice: Copyright © 2017 Terry et al.
– notice: Copyright © 2017 Terry et al. 2017 Terry et al.
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
ADTOC
UNPAY
DOI 10.1128/JVI.02119-16
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
Unpaywall for CDI: Periodical Content
Unpaywall
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList
MEDLINE - Academic
MEDLINE
CrossRef
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 3
  dbid: UNPAY
  name: Unpaywall
  url: https://proxy.k.utb.cz/login?url=https://unpaywall.org/
  sourceTypes: Open Access Repository
DeliveryMethod fulltext_linktorsrc
Discipline Biology
DocumentTitleAlternate FeLV Infection of Human Cells
EISSN 1098-5514
ExternalDocumentID 10.1128/jvi.02119-16
PMC5309941
28031367
10_1128_JVI_02119_16
Genre Research Support, Non-U.S. Gov't
Journal Article
Research Support, N.I.H., Extramural
GrantInformation_xml – fundername: Medical Research Council
  grantid: MR/K024752/1
– fundername: NCI NIH HHS
  grantid: R01 CA083823
– fundername: Medical Research Council
  grantid: MC_UU_12014/10
– fundername: Medical Research Council
  grantid: G0801822
– fundername: Cancer Research UK
  grantid: A11951
– fundername: Cancer Research UK
  grantid: 11951
– fundername: Bloodwise
  grantid: 13046
– fundername: HHS | NIH | National Cancer Institute (NCI)
  grantid: CA083823
– fundername: Cancer Research UK (CRUK)
  grantid: A11591
GroupedDBID ---
-~X
.55
.GJ
0R~
18M
29L
2WC
39C
3O-
4.4
41~
53G
5GY
5RE
5VS
6TJ
85S
AAFWJ
AAGFI
AAYJJ
AAYXX
ABPPZ
ACGFO
ACNCT
ADBBV
ADXHL
AENEX
AFFNX
AI.
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BTFSW
C1A
CITATION
CS3
D0S
DIK
E3Z
EBS
EJD
F5P
FRP
GROUPED_DOAJ
GX1
H13
HYE
HZ~
IH2
KQ8
MVM
N9A
O9-
OHT
OK1
P2P
RHI
RNS
RPM
RSF
TR2
UPT
VH1
W2D
W8F
WH7
WOQ
X7M
Y6R
YQT
ZGI
ZXP
~02
~KM
AGVNZ
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
ADTOC
UNPAY
ID FETCH-LOGICAL-c384t-f78ebaa42f4050ee067c203eaa597f9b938e8eeda4827580d0634b36448700f83
IEDL.DBID UNPAY
ISSN 0022-538X
1098-5514
1070-6321
IngestDate Wed Aug 20 00:09:37 EDT 2025
Tue Sep 30 16:58:53 EDT 2025
Thu Sep 04 16:29:11 EDT 2025
Mon Jul 21 06:02:30 EDT 2025
Thu Apr 24 22:53:11 EDT 2025
Wed Oct 01 01:46:03 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 5
Keywords feline leukemia virus
restriction factors
zoonosis
APOBEC
Language English
License Copyright © 2017 Terry et al.
This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license.
cc-by
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c384t-f78ebaa42f4050ee067c203eaa597f9b938e8eeda4827580d0634b36448700f83
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Citation Terry A, Kilbey A, Naseer A, Levy LS, Ahmad S, Watts C, Mackay N, Cameron E, Wilson S, Neil JC. 2017. Barriers to infection of human cells by feline leukemia virus: insights into resistance to zoonosis. J Virol 91:e02119-16. https://doi.org/10.1128/JVI.02119-16.
Present address: Asif Naseer, Khyber Medical University, Hayatabad, Peshawar, Khyber Pakhtunkhwa, Pakistan; Shamim Ahmad, Georgia Cancer Center, Augusta University, Augusta, Georgia, USA.
OpenAccessLink https://proxy.k.utb.cz/login?url=https://jvi.asm.org/content/jvi/91/5/e02119-16.full.pdf
PMID 28031367
PQID 1854106183
PQPubID 23479
ParticipantIDs unpaywall_primary_10_1128_jvi_02119_16
pubmedcentral_primary_oai_pubmedcentral_nih_gov_5309941
proquest_miscellaneous_1854106183
pubmed_primary_28031367
crossref_citationtrail_10_1128_JVI_02119_16
crossref_primary_10_1128_JVI_02119_16
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2017-03-01
PublicationDateYYYYMMDD 2017-03-01
PublicationDate_xml – month: 03
  year: 2017
  text: 2017-03-01
  day: 01
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: 1752 N St., N.W., Washington, DC
PublicationTitle Journal of virology
PublicationTitleAlternate J Virol
PublicationYear 2017
Publisher American Society for Microbiology
Publisher_xml – name: American Society for Microbiology
References e_1_3_2_26_2
e_1_3_2_49_2
e_1_3_2_28_2
e_1_3_2_41_2
e_1_3_2_20_2
e_1_3_2_43_2
e_1_3_2_22_2
e_1_3_2_45_2
e_1_3_2_24_2
e_1_3_2_47_2
Rojko JL (e_1_3_2_36_2) 1992; 66
e_1_3_2_9_2
e_1_3_2_16_2
e_1_3_2_37_2
e_1_3_2_7_2
e_1_3_2_18_2
e_1_3_2_39_2
e_1_3_2_54_2
e_1_3_2_10_2
e_1_3_2_31_2
e_1_3_2_52_2
e_1_3_2_5_2
e_1_3_2_12_2
e_1_3_2_33_2
e_1_3_2_58_2
e_1_3_2_3_2
e_1_3_2_14_2
e_1_3_2_35_2
e_1_3_2_56_2
e_1_3_2_50_2
e_1_3_2_27_2
e_1_3_2_48_2
e_1_3_2_29_2
e_1_3_2_40_2
e_1_3_2_21_2
e_1_3_2_42_2
e_1_3_2_23_2
e_1_3_2_44_2
e_1_3_2_25_2
e_1_3_2_46_2
e_1_3_2_15_2
e_1_3_2_38_2
e_1_3_2_8_2
e_1_3_2_17_2
e_1_3_2_6_2
e_1_3_2_19_2
e_1_3_2_30_2
e_1_3_2_53_2
e_1_3_2_32_2
e_1_3_2_51_2
e_1_3_2_11_2
e_1_3_2_34_2
e_1_3_2_57_2
e_1_3_2_4_2
e_1_3_2_13_2
e_1_3_2_55_2
e_1_3_2_2_2
References_xml – ident: e_1_3_2_48_2
  doi: 10.1128/JVI.00046-11
– ident: e_1_3_2_49_2
  doi: 10.1038/ncb2879
– ident: e_1_3_2_13_2
  doi: 10.1002/ijc.2910210103
– ident: e_1_3_2_56_2
  doi: 10.1128/jvi.38.2.688-703.1981
– ident: e_1_3_2_5_2
  doi: 10.1073/pnas.1304704110
– ident: e_1_3_2_52_2
  doi: 10.1128/JVI.02411-10
– ident: e_1_3_2_4_2
  doi: 10.1016/S0021-9258(18)47267-5
– ident: e_1_3_2_39_2
  doi: 10.1093/nar/gkh554
– ident: e_1_3_2_42_2
  doi: 10.1371/journal.ppat.1004145
– ident: e_1_3_2_30_2
  doi: 10.1016/j.virol.2010.11.011
– ident: e_1_3_2_22_2
  doi: 10.1128/jvi.71.11.8116-8123.1997
– ident: e_1_3_2_12_2
  doi: 10.1084/jem.182.5.1345
– ident: e_1_3_2_29_2
  doi: 10.1038/ni.3156
– ident: e_1_3_2_57_2
  doi: 10.1099/0022-1317-71-2-343
– ident: e_1_3_2_31_2
  doi: 10.1073/pnas.1217399110
– ident: e_1_3_2_7_2
  doi: 10.1038/2241208a0
– ident: e_1_3_2_26_2
  doi: 10.1038/296156a0
– ident: e_1_3_2_21_2
  doi: 10.1128/jvi.58.3.825-834.1986
– ident: e_1_3_2_41_2
  doi: 10.1016/0042-6822(80)90173-7
– ident: e_1_3_2_43_2
  doi: 10.1016/j.jmb.2004.01.046
– ident: e_1_3_2_10_2
  doi: 10.1371/journal.pone.0004744
– ident: e_1_3_2_34_2
  doi: 10.1292/jvms.70.1383
– ident: e_1_3_2_2_2
  doi: 10.1038/35057062
– ident: e_1_3_2_23_2
  doi: 10.1099/0022-1317-73-11-2839
– volume: 66
  start-page: 418
  year: 1992
  ident: e_1_3_2_36_2
  article-title: Lymphocytotoxic strains of feline leukemia-virus induce apoptosis in feline T4-thymic lymphoma-cells
  publication-title: Lab Invest
– ident: e_1_3_2_40_2
  doi: 10.1128/jvi.68.4.2458-2467.1994
– ident: e_1_3_2_55_2
  doi: 10.1128/JVI.02326-12
– ident: e_1_3_2_28_2
  doi: 10.1128/jvi.68.4.2151-2160.1994
– ident: e_1_3_2_33_2
  doi: 10.1007/s00705-011-0925-z
– ident: e_1_3_2_37_2
  doi: 10.1038/nature00939
– ident: e_1_3_2_38_2
  doi: 10.1073/pnas.74.5.1908
– ident: e_1_3_2_51_2
  doi: 10.1126/science.1251343
– ident: e_1_3_2_11_2
  doi: 10.2460/javma.2000.217.1475
– ident: e_1_3_2_25_2
  doi: 10.1128/JVI.73.8.6500-6505.1999
– ident: e_1_3_2_50_2
  doi: 10.1038/srep12230
– ident: e_1_3_2_44_2
  doi: 10.1006/viro.1994.1597
– ident: e_1_3_2_8_2
  doi: 10.1126/science.168.3935.1098
– ident: e_1_3_2_15_2
  doi: 10.1371/journal.pgen.1004167
– ident: e_1_3_2_27_2
  doi: 10.1126/science.287.5459.1828
– ident: e_1_3_2_9_2
  doi: 10.1128/CVI.00705-14
– ident: e_1_3_2_16_2
  doi: 10.1038/sj.onc.1209043
– ident: e_1_3_2_53_2
  doi: 10.7589/2014-04-114
– ident: e_1_3_2_19_2
  doi: 10.1016/0042-6822(71)90266-2
– ident: e_1_3_2_32_2
  doi: 10.1128/jvi.62.3.722-731.1988
– ident: e_1_3_2_35_2
  doi: 10.1038/nature16965
– ident: e_1_3_2_45_2
  doi: 10.1128/jvi.68.12.8296-8303.1994
– ident: e_1_3_2_54_2
  doi: 10.1186/1742-4690-9-112
– ident: e_1_3_2_24_2
  doi: 10.1182/blood.V95.3.1093.003k01_1093_1099
– ident: e_1_3_2_3_2
  doi: 10.1128/JVI.79.10.6478-6486.2005
– ident: e_1_3_2_58_2
  doi: 10.1038/332731a0
– ident: e_1_3_2_17_2
  doi: 10.1371/journal.pone.0154070
– ident: e_1_3_2_6_2
  doi: 10.1128/JVI.02745-15
– ident: e_1_3_2_46_2
  doi: 10.1128/JVI.00839-06
– ident: e_1_3_2_18_2
  doi: 10.1002/ijc.2910210314
– ident: e_1_3_2_20_2
  doi: 10.1128/JVI.80.7.3378-3385.2006
– ident: e_1_3_2_14_2
  doi: 10.1128/jvi.68.12.8001-8007.1994
– ident: e_1_3_2_47_2
  doi: 10.1128/MCB.01293-14
SSID ssj0014464
Score 2.2805552
Snippet The human genome displays a rich fossil record of past gammaretrovirus infections, yet no current epidemic is evident, despite environmental exposure to...
SourceID unpaywall
pubmedcentral
proquest
pubmed
crossref
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
SubjectTerms Animals
APOBEC-3G Deaminase - genetics
APOBEC-3G Deaminase - metabolism
Cats
Cell Line, Tumor
Disease Susceptibility
Gene Expression
Genome, Viral
HEK293 Cells
Humans
Leukemia Virus, Feline - physiology
Mutation
Retroviridae Infections - virology
Species Specificity
Viral Tropism
Virus Integration
Virus Replication
Virus-Cell Interactions
Zoonoses - virology
Title Barriers to Infection of Human Cells by Feline Leukemia Virus: Insights into Resistance to Zoonosis
URI https://www.ncbi.nlm.nih.gov/pubmed/28031367
https://www.proquest.com/docview/1854106183
https://pubmed.ncbi.nlm.nih.gov/PMC5309941
https://jvi.asm.org/content/jvi/91/5/e02119-16.full.pdf
UnpaywallVersion publishedVersion
Volume 91
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVAFT
  databaseName: Open Access Digital Library
  customDbUrl:
  eissn: 1098-5514
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0014464
  issn: 1098-5514
  databaseCode: KQ8
  dateStart: 19670201
  isFulltext: true
  titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html
  providerName: Colorado Alliance of Research Libraries
– providerCode: PRVBFR
  databaseName: Free Medical Journals
  customDbUrl:
  eissn: 1098-5514
  dateEnd: 20250403
  omitProxy: true
  ssIdentifier: ssj0014464
  issn: 1098-5514
  databaseCode: DIK
  dateStart: 19670101
  isFulltext: true
  titleUrlDefault: http://www.freemedicaljournals.com
  providerName: Flying Publisher
– providerCode: PRVFQY
  databaseName: GFMER Free Medical Journals
  customDbUrl:
  eissn: 1098-5514
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0014464
  issn: 1098-5514
  databaseCode: GX1
  dateStart: 0
  isFulltext: true
  titleUrlDefault: http://www.gfmer.ch/Medical_journals/Free_medical.php
  providerName: Geneva Foundation for Medical Education and Research
– providerCode: PRVAQN
  databaseName: PubMed Central
  customDbUrl:
  eissn: 1098-5514
  dateEnd: 20241003
  omitProxy: true
  ssIdentifier: ssj0014464
  issn: 1098-5514
  databaseCode: RPM
  dateStart: 19670101
  isFulltext: true
  titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/
  providerName: National Library of Medicine
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB7RrRBceEPDozIScEHZjfMOt1KxtBVUCLHV0kvkJBOxbZqsNglo-fXM5CWWFRLi6kwcOx57vrHH3wC8UDKVrpd4ukvLn24jOjrZmUBPMXKNWLJPwRv6H0_do5l9Mnfm3dYF34W5-M43uK6aM3wO1qaVl8smgZw4EzSYj0yX7pj3psfLJN2BXZdPlkawOzv9dPC15wanaTxvow3JObLa21fMnMn4oA9_N_3ma32dm4ZpC21uB03eqPOlWv9QWfabRZrehnnflzYQ5XJcV9E4_vkHzeN_dPYO3OpQqjho1eouXMP8Hlxv81au70P8Vq04010pqkIcd-FcuShS0ZwJiEPMslJEazHl2-4oPmB9iVcLJc4Wq7p8Q6-UvCdQikVOFXzGkkEsaR9Xd14UeUEFD2A2fffl8EjvsjXoseXblZ56PkZK2WZKGNBAJDMYm4aFSpHPkgZRYPnok0VWTDzq-EZC4MiOLPYPPcNIfeshjPIixz0QlgqknSgSUJ6dmk1SdtnQ2qg4SDDQ4HU_VGHcUZlzRo0sbFwa0w9Pzo7D5v-F0tXg5SC9bCk8_iL3vB_1kOYYH5yoHIu6DAnT2Ow6-5YGj1otGGri7F5Me6eBt6EfgwDzd28-yRffGh5vxyJ4bksNXg2atNVAUoehgY__VfAJ3DQZfTShck9hVK1qfEbYqYr2Yef9XO53s-UX1AMUpA
linkProvider Unpaywall
linkToUnpaywall http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwED9BJ8Re-GYLDGQk4AWlTeJ87m1MVNsEE0J0KrxETnIR3bKkahJQ-eu5y5coFRLi1bk4dnz2_c4-_w7gpTJT0_UST3dp-dNtREcnOxPoKUauEZvsU_CG_odz92Rmn82debd1wXdhLr_zDa7r5gyfg7Vp5eWySWBOnAkazEemm-6Y96bHyyS9CTsunyyNYGd2_vHoS88NTtN43kYbknMk29tXzJzJ-KAPf7f85mt9nZuGaQttbgdN3q7zpVr_UFn2m0Wa3oV535c2EOVqXFfROP75B83jf3T2HtzpUKo4atXqPtzA_AHcavNWrh9C_FatONNdKapCnHbhXLkoUtGcCYhjzLJSRGsx5dvuKN5jfYXXCyUuFqu6PKRXSt4TKMUipwo-YckglrSPq_taFHlBBY9gNn33-fhE77I16LH07UpPPR8jpWwrJQxoIJIZjC1DolLks6RBFEgffbLIiolHHd9ICBzZkWT_0DOM1JePYZQXOe6DkCow7USRgPLs1GqSspsNrY2KgwQDDd70QxXGHZU5Z9TIwsalsfzw7OI0bP5faLoavBqkly2Fx1_kXvSjHtIc44MTlWNRlyFhGptdZ19qsNdqwVATZ_di2jsNvA39GASYv3vzSb741vB4O5LguW1q8HrQpK0GkjoMDXzyr4JPYddi9NGEyh3AqFrV-IywUxU97-bJL13zE7M
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Barriers+to+Infection+of+Human+Cells+by+Feline+Leukemia+Virus%3A+Insights+into+Resistance+to+Zoonosis&rft.jtitle=Journal+of+virology&rft.au=Terry%2C+Anne&rft.au=Kilbey%2C+Anna&rft.au=Naseer%2C+Asif&rft.au=Levy%2C+Laura+S.&rft.date=2017-03-01&rft.issn=0022-538X&rft.eissn=1098-5514&rft.volume=91&rft.issue=5&rft_id=info:doi/10.1128%2FJVI.02119-16&rft.externalDBID=n%2Fa&rft.externalDocID=10_1128_JVI_02119_16
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0022-538X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0022-538X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0022-538X&client=summon